Human methylome studies SRP119706 Track Settings
 
DNA hypermethylation encroachment at CpG island borders in cancer is predisposed by H3K4 monomethylation [WGBS_Hs] [Adjacent Benign Normal Prostate, Prostate Tumor]

Track collection: Human methylome studies

+  All tracks in this collection (438)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       CpG reads ▾       HMR       PMD       CpG methylation ▾      
Select subtracks by views and experiment:
 All views AMR  CpG reads  HMR  PMD  CpG methylation 
experiment
SRX3267869 
SRX3267870 
SRX3267871 
SRX3267872 
SRX3267873 
SRX3267874 
SRX3267875 
SRX3267876 
SRX3267877 
SRX3267878 
SRX3267879 
SRX3267880 
SRX3267882 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX3267869  HMR  Adjacent Benign Normal Prostate / SRX3267869 (HMR)   Data format 
hide
 Configure
 SRX3267869  CpG methylation  Adjacent Benign Normal Prostate / SRX3267869 (CpG methylation)   Data format 
hide
 SRX3267870  HMR  Adjacent Benign Normal Prostate / SRX3267870 (HMR)   Data format 
hide
 Configure
 SRX3267870  CpG methylation  Adjacent Benign Normal Prostate / SRX3267870 (CpG methylation)   Data format 
hide
 SRX3267871  HMR  Adjacent Benign Normal Prostate / SRX3267871 (HMR)   Data format 
hide
 Configure
 SRX3267871  CpG methylation  Adjacent Benign Normal Prostate / SRX3267871 (CpG methylation)   Data format 
hide
 Configure
 SRX3267872  CpG methylation  Prostate Tumor / SRX3267872 (CpG methylation)   Data format 
hide
 Configure
 SRX3267873  CpG methylation  Prostate Tumor / SRX3267873 (CpG methylation)   Data format 
hide
 SRX3267874  HMR  Prostate Tumor / SRX3267874 (HMR)   Data format 
hide
 Configure
 SRX3267874  CpG methylation  Prostate Tumor / SRX3267874 (CpG methylation)   Data format 
hide
 SRX3267875  HMR  Prostate Tumor / SRX3267875 (HMR)   Data format 
hide
 Configure
 SRX3267875  CpG methylation  Prostate Tumor / SRX3267875 (CpG methylation)   Data format 
hide
 Configure
 SRX3267876  CpG methylation  Prostate Tumor / SRX3267876 (CpG methylation)   Data format 
hide
 SRX3267877  HMR  Prostate Tumor / SRX3267877 (HMR)   Data format 
hide
 Configure
 SRX3267877  CpG methylation  Prostate Tumor / SRX3267877 (CpG methylation)   Data format 
hide
 SRX3267878  HMR  Prostate Tumor / SRX3267878 (HMR)   Data format 
hide
 Configure
 SRX3267878  CpG methylation  Prostate Tumor / SRX3267878 (CpG methylation)   Data format 
hide
 SRX3267879  HMR  Prostate Tumor / SRX3267879 (HMR)   Data format 
hide
 Configure
 SRX3267879  CpG methylation  Prostate Tumor / SRX3267879 (CpG methylation)   Data format 
hide
 SRX3267880  HMR  Prostate Tumor / SRX3267880 (HMR)   Data format 
hide
 Configure
 SRX3267880  CpG methylation  Prostate Tumor / SRX3267880 (CpG methylation)   Data format 
hide
 SRX3267882  HMR  Prostate Tumor / SRX3267882 (HMR)   Data format 
hide
 Configure
 SRX3267882  CpG methylation  Prostate Tumor / SRX3267882 (CpG methylation)   Data format 
    
Assembly: Human Dec. 2013 (GRCh38/hg38)

Study title: DNA hypermethylation encroachment at CpG island borders in cancer is predisposed by H3K4 monomethylation [WGBS_Hs]
SRA: SRP119706
GEO: GSE104789
Pubmed: 30753827

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX3267869 Adjacent Benign Normal Prostate 0.721 9.9 59425 1182.2 262 1051.1 959 21239.1 0.982 GSM2807933: 3640_benign_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267870 Adjacent Benign Normal Prostate 0.740 11.4 57417 1092.6 532 1190.8 955 19976.3 0.982 GSM2807934: 24023_benign_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267871 Adjacent Benign Normal Prostate 0.726 9.8 48249 1204.8 475 991.3 774 21985.9 0.981 GSM2807935: 3131_benign_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267872 Prostate Tumor 0.707 8.8 67095 7318.9 608 928.5 1562 430215.8 0.974 GSM2807936: 3131_tumor_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267873 Prostate Tumor 0.663 7.6 62273 7058.2 385 878.8 1631 511633.7 0.967 GSM2807937: 514C_tumor_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267874 Prostate Tumor 0.718 4.8 34575 1842.6 182 985.2 812 693328.0 0.929 GSM2807938: 408C_tumor_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267875 Prostate Tumor 0.744 13.5 44205 1628.8 1332 1021.1 1379 372788.4 0.956 GSM2807939: 1601C_tumor_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267876 Prostate Tumor 0.687 8.8 51454 6348.8 2579 7963.2 1571 527312.3 0.982 GSM2807940: 3640_tumor_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267877 Prostate Tumor 0.738 6.6 31547 1251.8 1603 1021.1 158 47196.8 0.948 GSM2807941: 1579C_tumor_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267878 Prostate Tumor 0.685 5.2 32572 1371.4 1014 1000.5 104 49310.1 0.936 GSM2807942: 356C_tumor_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267879 Prostate Tumor 0.697 10.5 35938 1607.8 1633 1025.3 1197 681142.5 0.948 GSM2807943: 204C_tumor_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267880 Prostate Tumor 0.672 6.4 35472 1346.3 1926 1052.5 455 45986.5 0.957 GSM2807944: 294C_tumor_prostate_WGBS; Homo sapiens; Bisulfite-Seq
SRX3267882 Prostate Tumor 0.676 10.4 41511 2297.4 2500 954.3 1577 563776.7 0.980 GSM2807946: 24023_tumor_prostate_WGBS; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.